Publicaciones en colaboración con investigadores/as de London School of Hygiene & Tropical Medicine (5)

2022

  1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

  2. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 3, pp. 291-301

2021

  1. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: The results of the AFFIRM-AHF study

    European Heart Journal, Vol. 42, Núm. 31, pp. 3011-3020

2020

  1. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

    The Lancet, Vol. 396, Núm. 10266, pp. 1895-1904

2019

  1. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure

    European Journal of Heart Failure, Vol. 21, Núm. 12, pp. 1651-1658